GENova Biotherapeutics signs collaboration agreement with Bridge Bioresearch.
GENova's business solely focuses on cancer cures, while Bridge BioResearch is geared at acquiring drug targets for Obesity and Type 2 Diabetes. Through the collaboration agreement, the two companies will partner to share research results and their global contacts with research organizations and pharmaceutical companies. They will also examine their findings to gain insight into the links between their respective fields of oncology and obesity, as cancer and obesity are both maladies that can be blamed on lifestyle choices.
"By collaborating with Bridge BioResearch, we will gain access to their excellent network of high quality research labs and universities around the world, as well as their well-established distribution channels," says Aaron Whiteman, CEO for GENova. "We are confident that through this collaboration, we will gain access to the latest and greatest in developmental cancer drugs to perpetuate our acquisition pipeline, as well as secure reliable distribution channels for our out-licensing objectives."
"Furthermore, through this collaboration, we will exchange our scientific findings to gain insight into the links between obesity and cancer, as many findings suggest that one of the main factors in cancer development is lifestyle choices, including unhealthy diet," says Whiteman.
Bridge BioResearch is a drug discovery company with the sole corporate focus on Obesity, Type 2 Diabetes and related metabolic disorders. It has research cooperation agreements with leading Research and Development Services providers and bioscience research institutions and universities throughout Asia and Europe. The company uses a cost-efficient technology and patent acquisition strategy for proprietary intellectual property from identified companies, government institutions and universities, paid via milestone-dependent research collaborations and grants.
GENova is positioning itself as a leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers.
GENova Biotherapeutics, Inc.
Bridge BioResearch Plc
|Printer friendly Cite/link Email Feedback|
|Publication:||BIOTECH Patent News|
|Date:||Aug 1, 2009|
|Previous Article:||Appeals Court affirms patent infringement rulings against Roche's peg-EPO product.|
|Next Article:||RZN Nutraceuticals receives United States Patent and Trademark Office notice of allowance for proprietary HerbaZorb absorption and delivery.|